Get access

High rate of long-term virological response after a 1-year course of interferon ± ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial


Eveline Boucher, MD, Centre Eugène Marquis, 35062 Rennes cedex, France.
Tel: (33) 299 25 31 80.
Fax: (33) 299 25 32 50.


We investigated the long-term efficacy of a 12-month course of interferon (IFN)+ribavirin in chronic hepatitis C relapsers. We randomized 191 relapsers with a 2:1 ratio to receive 3 million units three times a week of interferon alpha (IFN α)-2b+ribavirin (1–1.2 g/day) (group A=127 patients) or IFN α-2b (group B=60 patients) of same dosage and duration for 1 year. General and hepatitis C data of group A and B patients were similar. The main goal of the study was to determine the rate of sustained virological response evaluated 1 year after treatment.

Results: Virological sustained response (SR) was 61% and 12% for groups A and B, respectively (P<0.001). A significant histological improvement was observed in both treatment groups. The Metavir activity score became significantly lower in the IFN+ribavirin group than in the IFN group (P<0/0001). The Metavir fibrosis scores remained unchanged. Also, at the end of the treatment, the virological response was 69% (88/127) for group A and 33% (20/60) for group B (P<0.001).

Conclusion: One-year retreatment of relapsers with the combination of IFN+ribavirin led to 61% of virological SR and to a significant improvement of histological activity. Therefore, the therapeutic schedule presented here can be considered of particular interest for the retreatment of relapsers.

Get access to the full text of this article